CPRR04-EFC4690/TROG 02.02 - HEADSTART

By w.paterson
14 August, 2021
0 Comments

"Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine (SR259075) Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer"

Primary Sponsor

1 October, 2024

A plan for the future of cancer research

12 September 2024: TROG Cancer Research has outlined how

TOPGEAR trial results published in the New England Journal of Medicine

18 September, 2024

TOPGEAR trial findings published in NEJM

18 September 2024: We’re thrilled to announce the release

Join us to raise $20,000

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

"Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine (SR259075) Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer"

TROG 03.02

ANZMTG 01.02/TROG 02.01

Related Post

A plan for the future of cancer research

TOPGEAR trial findings published in NEJM

Join us to raise $20,000

CPRR04-EFC4690/TROG 02.02 – HEADSTART

"Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine (SR259075) Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer"

TROG 03.02

ANZMTG 01.02/TROG 02.01

Related Post

A plan for the future of cancer research

TOPGEAR trial findings published in NEJM

Join us to raise $20,000